Compare Cognizant Technology Solutions Corp (CTSH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Tempus AI — how do they compare? Cognizant Technology Solutions Corp trades at $60.12 (market cap $25.71B), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Cognizant Technology Solutions Corp is far larger — about 2× Tempus AI's market cap, and Cognizant Technology Solutions Corp pays a 2.31% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Tempus AI for 22 Days on average.
| CTSH | TEM | |
|---|---|---|
Market Cap | $25.71B | $12.77B |
Volume | 5,152,376 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $86.70 | $99.28 |
52-Week Low | $38.73 | $41.55 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | $26.75B | $13.40B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 4.88% on the day, with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.25 and net income margin of 10.26%, while revenue grew to $21.11B in 2025. Analyst consensus is mixed with a $64.25 price target, and the company continues to gain recognition for AI-driven initiatives and workplace excellence.
CTSH presents a balanced outlook with undervalued metrics and strong cash flow, but faces headwinds from technical bearishness and competitive IT spending pressures. The upcoming Q3 2026 earnings on October 29, 2026, will be critical for confirming growth trajectory amid evolving AI integration strategies.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
